Sponsor or institution
Clinical trials and research at Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
As of November 12, 2026, Find a Trial lists 29 clinical trials run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that are recruiting, in China. By phase: Phase 2 (14), Phase 1 (9), Phase 1/2 (4), Phase 3 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 29Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Test of SKB575 in adults with asthma | Phase 1 | Chengdu, Sichuan and 1 other locations | Recruiting | Jul 28, 2026 |
| SKB500 combinations for esophageal squamous cell carcinoma | Phase 2 | Changchun and 23 other locations | Recruiting | Jul 14, 2026 |
| SKB264 plus SKB118 in NSCLC (phase 2) | Phase 2 | Jilin City and 1 other locations | Recruiting | Jul 13, 2026 |
| SKB571 in recurrent or metastatic head and neck cancer in adults | Phase 2 | Chengdu and 1 other locations | Recruiting | Jun 25, 2026 |
| SKB571-based combination therapy for NSCLC | Phase 2 | Beijing, Beijing Municipality and 26 other locations | Recruiting | Jun 3, 2026 |
| SKB118 Injection in Advanced Solid Tumors (Part 1: monotherapy; Part 2: in combination with SKB264) | Phase 1/2 | Shanghai, Shanghai Municipality | Recruiting | May 14, 2026 |
| SKB571 in Gastrointestinal Tumors | Phase 2 | Chongqing, Chongqing Municipality and 25 other locations | Recruiting | May 4, 2026 |
| SKB565 injection for advanced solid tumors | Phase 1/2 | Guangzhou, Guangdong and 1 other locations | Recruiting | Apr 22, 2026 |
| SKB575 (HBM7575) injection in healthy adults and adults with atopic dermatitis | Phase 1 | Shanghai and 1 other locations | Recruiting | Mar 23, 2026 |
| SKB103 injection for advanced solid tumors | Phase 1/2 | Harbin, Heilongjiang and 1 other locations | Recruiting | Mar 10, 2026 |
All recruiting trials (29)
-
Test of SKB575 in adults with asthma
This study tests whether SKB575 helps people with asthma compared to a placebo.
-
SKB500 combinations for esophageal squamous cell carcinoma
This study tests SKB500 combined with other drugs to see if it is safe and shows early signs of activity in adults with unresectable or metastatic esophageal squamous cell carcinoma who have limited prior treatment.
-
SKB264 plus SKB118 in NSCLC (phase 2)
This phase 2 study tests whether the drug combo SKB264 and SKB118 is safe and helpful for people with NSCLC who don’t have certain mutations.
-
SKB571 in recurrent or metastatic head and neck cancer in adults
This study tests SKB571, alone or with Pembrolizumab and platinum chemotherapy, to see if it helps adults with recurrent or metastatic head and neck cancer.
-
SKB571-based combination therapy for NSCLC
This phase 2 study tests a SKB571-based combination treatment in adults with non-small cell lung cancer to see if it is safe and shows signs of anti-tumor activity.
-
SKB118 Injection in Advanced Solid Tumors (Part 1: monotherapy; Part 2: in combination with SKB264)
This study tests SKB118 alone and in combination with SKB264 to see if it is safe and can help people with advanced solid tumors who have few or no other options.
-
SKB571 in Gastrointestinal Tumors
A Phase 2, open-label study tests SKB571 in adults with gastrointestinal tumors to see if it is safe and may help shrink tumors.
-
SKB565 injection for advanced solid tumors
This phase 1/2 study tests SKB565 in adults with advanced solid tumors who have exhausted or cannot tolerate standard therapies.
-
SKB575 (HBM7575) injection in healthy adults and adults with atopic dermatitis
This trial will test whether SKB575 (HBM7575) injection is safe and how it behaves in healthy adults and in adults with moderate to severe atopic dermatitis.
-
SKB103 injection for advanced solid tumors
This study tests a SKB103 injection to see if it is safe and effective for adults with advanced solid tumors who have limited treatment options.
-
SKB518 alone or with carboplatin and bevacizumab for advanced gynecologic cancers
This trial will test SKB518, given alone or with carboplatin and/or bevacizumab, in adults with advanced ovarian, cervical, or endometrial cancer to see if it controls the disease and is safe.
-
SKB105 injection for advanced solid tumors
This Phase 1/2 trial will try SKB105 in adults with advanced solid tumors to see if it is safe, well tolerated, and can slow or shrink tumors.
-
Neoadjuvant sacituzumab tirumotecan with or without osimertinib for resectable EGFR‑mutated non‑small cell lung cancer
This trial will test whether giving sacituzumab tirumotecan alone or together with osimertinib before surgery helps people with resectable EGFR‑mutated non‑small cell lung cancer.
-
Sacituzumab Tirumotecan for locally advanced or metastatic thymic carcinoma
This trial tests whether Sac-TMT can help people with thymic carcinoma after one prior platinum-based therapy.
-
SKB571 as a single treatment for advanced or metastatic non-small cell lung cancer with MET abnormalities
This trial will try SKB571 alone in adults with locally advanced or metastatic non-small cell lung cancer that has MET abnormalities and has progressed after standard treatments.
-
A166 for HER2-positive advanced or metastatic breast cancer
This trial will test whether A166 helps adults with HER2-positive unresectable or metastatic breast cancer who previously received a topoisomerase inhibitor–based HER2 antibody-drug conjugate.
-
SKB500 combination treatments for extensive-stage small cell lung cancer
This trial tests SKB500 given with other medicines in adults with extensive-stage small cell lung cancer to see if the combinations are safe and show tumor-fighting activity.
-
Phase II test of SKB571 for advanced non-small cell lung cancer
This study will test SKB571 given alone in adults with advanced non-small cell lung cancer to see if it is safe and can shrink tumors.
-
SKB107 for advanced solid tumors that have spread to bone
This trial will test SKB107 in adults whose solid tumors have metastasized to bone to see if the drug is safe, how it behaves in the body, and whether it shows signs of benefit.
-
SKB264 versus investigator's choice chemotherapy for unresectable or metastatic HR+/HER2- breast cancer
This will test whether SKB264 works better than commonly chosen chemotherapy for adults with unresectable or metastatic HR+/HER2- breast cancer who no longer benefit from hormone therapy.
-
SKB518 treatment for people with lung cancer
This trial will test whether SKB518 given alone is safe and can shrink tumors in adults with non-small cell or small cell lung cancer.
-
SKB445 injection for treating advanced solid tumors
This study is testing a new injection called SKB445 to see if it can safely help people with advanced solid tumors.
-
Evaluating SKB500 for advanced solid tumors
This study is testing a new treatment called SKB500 to see if it is safe and effective for people with advanced solid tumors.
-
Evaluating MK-6204 for advanced solid tumors
This study is testing a new drug called MK-6204 to see if it is safe and effective for people with advanced solid tumors.
-
SKB571 for adults with advanced solid tumors
This first-in-human Phase 1 test gives SKB571 to adults with advanced or metastatic solid tumors to see if it is safe, how the body handles it, and whether it shows anti-tumor activity.
-
SKB518 treatment for adults with advanced solid tumors
This tests SKB518, an experimental injectable drug, in adults with advanced or metastatic solid tumors that have progressed after or are ineligible for standard treatments.
-
Evaluating SKB264 for advanced breast cancer
This study is testing a new drug called SKB264 to see if it can help people with advanced breast cancer that hasn't responded to other treatments.
-
Evaluating SKB315 for patients with advanced solid tumors
This study is testing a new treatment called SKB315 to see if it is safe and effective for people with advanced solid tumors.
-
Combination therapy for advanced non-small cell lung cancer
This study is testing a new combination treatment for advanced lung cancer to see if it is safe and helps patients feel better.
Quick answers
How many clinical trials run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. are recruiting right now?
29, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 14, Phase 1: 9, Phase 1/2: 4, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.